Announcements Trials
Browse Landscape

Phase

Phase 2 16Phase 1/2 3Phase 1 3Phase 3 2Phase 2/3 2Phase NA 1Phase 4 1

Status

Not yet recruiting 1Active not recruiting 1

Sponsor Class

NETWORK 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 4Sarcoma 2CNS 1

Conditions

Sarcoma, Ewing 1Gastrointestinal Stromal Tumors 1

Interventions

Doxorubicin 7Radiotherapy 4Radiation 3Magnetic Resonance Spectroscopy 3Ifosfamide 3regorafenib 2Temozolomide 2Surgical Procedures, Operative 2Methotrexate 2Imatinib Mesylate 2Etoposide 2Drug Therapy 2Cyclophosphamide 2Cisplatin 2veliparib 1selinexor 1pirarubicin 1pazopanib 1niraparib 1merphos 1liposomal doxorubicin 1fludarabine phosphate 1dostarlimab 1capmatinib 1cabozantinib 1brigimadlin 1apatinib 1anlotinib 1Zoledronic Acid 1X-Rays 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × regorafenib × Sarcoma × Clear all
NCT07379047 2026-04-24

GISTAR-1

Ningbo Newbay Technology Development Co., Ltd

Phase 2/3 Not yet recruiting
255 enrolled
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT06820957 2026-02-17

Testing a New Combination of Anti-cancer Drugs in Patients Newly Diagnosed With Ewing Sarcoma Who Have Cancer That Has Spread to Other Parts of the Body

Children's Oncology Group

Phase 2/3 Active not recruiting
437 enrolled
Sarcoma

Sarcoma, Ewing

Data powered by HemOnc (CC BY 4.0) Colophon âš¡